Neda Razavi
CEO & Chairwoman
iSono Health
Neda Razavi is the CEO of iSono Health, a company redefining breast cancer detection through the convergence of AI, robotics, and 3D ultrasound. Under her leadership, iSono is creating a new category of imaging that eliminates reliance on sonographers, delivers MRI-like 3D breast images in minutes, and brings advanced diagnostics to every clinic. She initially invested in iSono Health after recognizing its transformative potential before the company achieved FDA clearance—and now leads it into commercialization and global expansion.
With 25 years of experience bringing innovative medical technologies to patients and clinicians, Neda has launched 65 products across six global
platforms, generating over $9 billion in cumulative revenue. She has held leadership roles at Illumina, Roche, Abbott Laboratories, Medtronic, Baxter
Bioscience (now Takeda), Kythera (acquired by Allergan), and Natera, building deep expertise in oncology, women’s health, and diagnostics.
At Illumina, Neda served as Clinical Marketing Director, leading a global team of 10 senior marketers and 450 cross-functional collaborators to achieve $1.7B in annual revenue.
At Roche, she led the commercialization of a clinical-research sequencing platform with $1.9B in projected revenue and $60M+ in annual joint development agreements, managing over 600 stakeholders.
At Abbott Laboratories, she introduced a new category of coagulation testing systems in partnership with Sekisui, driving a $2.5B revenue projection.
During her tenure at Medtronic, she uncovered $650M in new market opportunities in Type II diabetes and brokered a strategic partnership with
Sanofi for global distribution.
Prior to joining iSono Health, Neda also led Stanford Emergence’s Industry Affiliates Program, building the foundation for academic–industry collaboration and entrepreneurial ecosystem development. In addition to her corporate leadership, she has advised and invested in multiple healthcare
startups, helping founders raise funds, craft go-to-market strategies, and build scalable partnerships.
A cellular microbiologist by training with an MBA in Finance, Neda combines scientific depth with business acumen to drive innovation and enterprise value.
Her career is defined by a singular mission — to make early detection and precision healthcare accessible to all, and to transform how and where
life-saving technologies reach patients
With 25 years of experience bringing innovative medical technologies to patients and clinicians, Neda has launched 65 products across six global
platforms, generating over $9 billion in cumulative revenue. She has held leadership roles at Illumina, Roche, Abbott Laboratories, Medtronic, Baxter
Bioscience (now Takeda), Kythera (acquired by Allergan), and Natera, building deep expertise in oncology, women’s health, and diagnostics.
At Illumina, Neda served as Clinical Marketing Director, leading a global team of 10 senior marketers and 450 cross-functional collaborators to achieve $1.7B in annual revenue.
At Roche, she led the commercialization of a clinical-research sequencing platform with $1.9B in projected revenue and $60M+ in annual joint development agreements, managing over 600 stakeholders.
At Abbott Laboratories, she introduced a new category of coagulation testing systems in partnership with Sekisui, driving a $2.5B revenue projection.
During her tenure at Medtronic, she uncovered $650M in new market opportunities in Type II diabetes and brokered a strategic partnership with
Sanofi for global distribution.
Prior to joining iSono Health, Neda also led Stanford Emergence’s Industry Affiliates Program, building the foundation for academic–industry collaboration and entrepreneurial ecosystem development. In addition to her corporate leadership, she has advised and invested in multiple healthcare
startups, helping founders raise funds, craft go-to-market strategies, and build scalable partnerships.
A cellular microbiologist by training with an MBA in Finance, Neda combines scientific depth with business acumen to drive innovation and enterprise value.
Her career is defined by a singular mission — to make early detection and precision healthcare accessible to all, and to transform how and where
life-saving technologies reach patients
